A5088814208- Urinary Bladder and Prostate Research
- Electrolyte and hormonal disorders
- Urinary Tract Infections Management
- Bladder and Urothelial Cancer Treatments
- Pelvic floor disorders treatments
- Urticaria and Related Conditions
- Ion Transport and Channel Regulation
- Neuroendocrine regulation and behavior
- Sexual function and dysfunction studies
- Stoma care and complications
- Colorectal Cancer Surgical Treatments
- Pediatric Urology and Nephrology Studies
- Sympathectomy and Hyperhidrosis Treatments
- Circadian rhythm and melatonin
- Sleep and related disorders
- Hormonal Regulation and Hypertension
- Sleep and Wakefulness Research
- Genetic and Kidney Cyst Diseases
- Obstructive Sleep Apnea Research
- Helicobacter pylori-related gastroenterology studies
- Sexual Differentiation and Disorders
- Anorectal Disease Treatments and Outcomes
- Food Allergy and Anaphylaxis Research
- Cancer Research and Treatments
- Dialysis and Renal Disease Management
Ferring Pharmaceuticals (Denmark)
2015-2025
Ghent University Hospital
2018
Ghent University
2013-2016
Ferring Pharmaceuticals (Switzerland)
2012-2014
Coloplast (Denmark)
2008
Herlev Hospital
1999
Hvidovre Hospital
1999
National Board of Health
1998
Open AccessJournal of UrologyAdult Urology5 May 2024Efficacy Intravesical Nadofaragene Firadenovec for Patients with BCG-Unresponsive Non–muscle Invasive Bladder Cancer: 5 Year Follow-Up from a Phase 3 Trial Vikram M. Narayan, Stephen A. Boorjian, Mehrdad Alemozaffar, Badrinath R. Konety, Neal D. Shore, Leonard G. Gomella, Ashish Kamat, Trinity J. Bivalacqua, Jeffrey S. Montgomery, Seth P. Lerner, Joseph E. Busby, Michael Poch, Paul L. Crispen, Gary Steinberg, Anne K. Schuckman, Tracy Downs,...
Increased age and female gender are well-known risk factors for the development of desmopressin-induced hyponatremia. However, little focus has been on exploring differences in antidiuretic response to desmopressin. Based an exploratory analysis from three clinical trials, we report a significant difference effects desmopressin nocturnal urine volume that could not be explained by pharmacokinetic differences. Mean concentration profiles were tested covariates, statistically only weight was...
Abstract Background Quality of life stoma patients is increasingly being addressed in clinical trials. However, the instruments used majority these studies have not been validated specifically for patients. The aim this paper to describe development and validation a quality-of-life instrument, "Stoma-QOL", with colostomy or ileostomy. Methods Potential items were formulated English on basis results series semi-structured interviews 169 adult process resulted preliminary 37-item version,...
In recent years, there have been several improvements in the treatment of neurohypophyseal diabetes insipidus (DI). They include new formulations vasopressin analog, desmopressin; a better understanding effect fluid intake on dosing; and more information about treatments infants, children, pregnant women who present special challenges. This review aims to summarize past current relative safety efficacy for types DI caused by primary deficiency vasopressin. The is based publications...
Objective. Peristomal bulging caused by hernia or prolapse is common in patients with a sigmoidostomy. It not known whether and to what extent peristomal influences various daily activities. The purpose of this study was evaluate the effects using general disease-specific health scale (Short Health Scale, SHS) stoma-specific quality life (Stoma-QoL) questionnaire without bulging. Material methods. Seventy sigmoidostomies were examined identify mean (SD) age 71.7 (13.7) years had their for...
TPS891 Background: Bacillus Calmette-Guérin (BCG) is the standard first-line therapy for patients with high-risk non–muscle-invasive bladder cancer (NMIBC) carcinoma in situ (CIS) ± papillary tumors; however, whose disease unresponsive to BCG are unlikely benefit from further courses of BCG. Bladder-preserving treatment options BCG-unresponsive NMIBC CIS Ta/T1 include intravesical gene (nadofaragene firadenovec-vncg), chemotherapy (gemcitabine and docetaxel), immunotherapy (intravenous...
TPS888 Background: There is currently no Food and Drug Administration (FDA)-approved treatment for intermediate-risk non–muscle-invasive bladder cancer (IR NMIBC), defined by the AUA as recurrence of low-grade (LG) Ta within 1 year, solitary LG >3 cm, multifocal Ta, high-grade (HG) (≤3 cm), and/or T1. Nadofaragene firadenovec-vncg first FDA-approved intravesical nonreplicating gene therapy adult patients with high-risk Bacillus Calmette Guérin (BCG)-unresponsive NMIBC carcinoma in situ...
No AccessJournal of UrologyPediatric Article17 Mar 2025Childhood functional urinary incontinence and school performance: a nationwide matched cohort study Britt Borg, MD, PhD Betina B. Trabjerg, Julie Werenberg Dreier, Søren Rittig, MD DMSc Anders Breinbjerg, Jakob Christensen, Kristian Juul, Per Hove Thomsen, andMD Konstantinos KamperisMD BorgBritt Borg Corresponding author – ([email protected]) - +4522740973 https://orcid.org/0009-0002-0166-9999 , TrabjergBetina Trabjerg National Centre...
What's known on the subject? and What does study add? Desmopressin orally disintegrating tablet ( ODT ) 60–240 μg has proved an effective well‐tolerated antidiuretic treatment in male female patients with nocturia. The main adverse event is hyponatraemia. Recent studies suggest that are more sensitive to desmopressin , achieving same efficacy at lower doses than patients. demonstrates of Japanese It provides further evidence optimum dose for nocturia females males. Tailoring according gender...
Objective To explore risk factors for desmopressin‐induced hyponatraemia and evaluate the impact of a serum sodium monitoring plan. Subjects Methods This was meta‐analysis data from three clinical trials desmopressin in nocturia. Patients received placebo or orally disintegrating tablet ( ODT ; 10–100 μg). The incidence <130 mmol/L recorded by age, sex dose. Potential predictors clinically significant were identified using multivariate analysis Cox proportional hazards model. Results...
Central diabetes insipidus (CDI) is associated with arginine vasopressin (AVP) deficiency resultant polyuria and polydipsia. Intranasal desmopressin provides physiological replacement but oral formulations are preferred for their ease of administration. This study aimed to demonstrate the efficacy safety orally disintegrating tablet (ODT) in treatment Japanese patients CDI, confirm that antidiuresis maintained on switching from intranasal ODT. A total 20 aged 6–75 years CDI were included...
Abstract Primary nocturnal enuresis is a prevalent childhood condition that can persist into adulthood. Desmopressin an antidiuretic available as orally disintegrating lyophilisate (melt) or solid tablet. Recent findings suggesting different food interactions and clinical characteristics, including compliance, between desmopressin melt tablet motivated post hoc analysis of previously reported randomised, crossover study. The efficacy compared with was evaluated using the International...
Epidemiological data for central diabetes insipidus (CDI) are sparse.The purpose of this study was to provide accurate epidemiological on CDI a national level.This drug utilization and patient registry during 5-year period from 2007 2011.We used the Danish National Prescription Registry linked with Patient epidemiology using waiting time distribution other pharmacoepidemiological methods.A total 1285 patients were recorded in observation given 9309 prescriptions desmopressin nasal...
Objective Evaluation of safety and efficacy desmopressin/tolterodine combination therapy in women. Methods This double‐blind, randomized, proof‐of‐concept study enrolled 106 patients (≥18 years), with overactive bladder ( OAB ) nocturia, ≥2 nocturnal voids, receiving a 3‐month once‐daily (desmopressin 25 µg, orally‐disintegrating tablets [ ODT ]/tolterodine 4 mg [Detrol® LA ]; n = 49) or monotherapy (tolterodine mg/placebo ; 57). Primary endpoint was change from baseline mean number voids....
Abstract This study assessed the efficacy and safety of desmopressin orally disintegrating tablets (ODTs) in Japanese males (50 25 μg) females (25 with nocturia due to nocturnal polyuria (NP). Two Phase 3 randomized double‐blind placebo‐controlled studies 342 190 NP were conducted. The primary endpoint was change from baseline mean number voids. In addition, time first awakening void, urine volume, index (NPI), quality life during a 12‐week treatment period. males, 50 μg ODTs significantly...
BackgroundThe prevalence of nocturnal polyuria (NP), which is passing large volumes urine during the main sleep period, has been investigated primarily in middle-aged to older men. There thus a gap NP evidence base for women and younger individuals.ObjectiveTo estimate nocturia due USA.Design, setting, participantsThis epidemiologic study used US population-representative sample men aged ≥30 yr assess (NCT04125186).Outcome measurements statistical analysisConsenting participants completed an...
Desmopressin is a synthetic analogue of vasopressin and selective receptor 2 agonist. It was first synthesised in 1967 utilised for its antidiuretic properties. also used bleeding disorders to enhance clotting. Other potential uses the drug have been reported. The present review aims provide broad overview literature on further oral forms desmopressin. Key therapeutic areas interest were identified based known physiological activities/targets desmopressin or reports an effect literature....